Immuneering Corporation

IMRX

Healthcare Biotechnology

Immuneering Corporation’s revenue for fiscal 2022 (year ended December 2022) was $317,000.00.

EPS
+1.61%
Free cash flow
−40.2%

Quarter to September 2026, against a year earlier

3.68 0.31 +9.20%
Market cap
$238.3M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
3/9
ROIC
−198.4%
Net debt / EBITDA
2.9×
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Total current assets
150.71 157.99 161.41 176.25
Total non-current assets
31.85 44.06 53.40 55.74
Total Assets
182.56 202.06 214.81 231.99
Total current liabilities
10.79 8.12 4.97 10.07
Total non-current liabilities
3.09 3.20 3.32 3.43
Total liabilities
13.88 11.32 8.29 13.50
Common Equity (Total)
168.68 190.74 206.52 218.48
Shareholders Equity (Total)
168.68 190.74 206.52 218.48

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 6 Nov 2026